ClinicalTrials.gg
CompletedNCT02049515Updated Sep 21, 2023Results posted

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

A Phase 3 interventional study of IPI-145 and Ofatumumab in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by SecuraBio. Completed at 69 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by SecuraBio · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
99
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 2 under way, none of them phase 3. duvelisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
2nd of 12
99 · median 11
Started
2013
with 2 others
Phase 3
3 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
5 of 12
SecuraBio

Among the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is one of 3 in phase 3, and was the 3rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About duvelisib

duvelisib: first FDA approval 2018 (COPIKTRA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing duvelisib in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 (duvelisib) monotherapy or ofatumumab monotherapy in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with IPI-145 or ofatumumab in study IPI-145-07 (NCT02004522).

Read the detailed description

The study was designed as an open-label, two-arm extension evaluation to enable participants who experienced radiologically confirmed disease progression in study IPI-145-07 to receive the alternative treatment (either IPI-145 or ofatumumab) other than what was received during study IPI-145-07.

Participants who previously had received ofatumumab in study IPI-145-07 received a starting dose of 25 milligrams (mg) IPI-145 twice daily continuously in a 21-day cycle for Cycle 1, followed by 28-day treatment cycles thereafter for up to 11 cycles or until disease progression, discontinuation from study participation, or start of subsequent therapy, whichever occurred first. After completing approximately 11 cycles of treatment with duvelisib, participants who, in the judgment of the investigator, may have derived benefit from continued treatment may have continued to receive additional cycles of duvelisib until disease progression or unacceptable toxicity. However, to receive additional cycles of duvelisib beyond 11 cycles, participants must have had evidence of response and CLL/SLL requiring treatment according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/International Working Group by Cycle 12 Day 1.

Participants who previously received IPI-145 in study IPI-145-07 received treatment consistent approved product labeling which consisted of a starting dose of 300 mg ofatumumab on Day 1, followed by seven weekly doses of 2000 mg. Thereafter, participants received 2000 mg ofatumumab once every month for four months unless disease progression or unacceptable toxicity occurred. Administration of ofatumumab was not to exceed the 12 doses (within 7 cycles).

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Phase 3
  • CLL/SLL
  • PI3K
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received either IPI-145 or ofatumumab while participating in study IPI-145-07 and experienced radiologically confirmed disease progression
  • Diagnosis of active CLL or SLL that met at least one of the IWCLL 2008 criteria for requiring treatment
  • with a lymph node or tumor mass >1.5 centimeters in at least one dimension as assessed by computed tomography (CT)
  • performance status of 0-2
  • Must have met the following laboratory parameters:

    1. Serum (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤3 x (ULN)
    2. Total ≤1.5 x ULN
    3. Serum creatinine ≤2.0 x ULN
    4. ≥8.0 grams/deciliter (g/dL) with or without transfusion support
    5. count ≥10,000 microliters (μL) with or without transfusion support
  • For women of (WCBP): negative serum β-human chorionic gonadotropin pregnancy test within one week before first dose (WCBP defined as a sexually mature woman who had not undergone surgical sterilization or who had not been naturally for at least 24 consecutive months [women ≤55 years] or 12 consecutive months [women >55 years])
  • Willingness of male and female participants who were not surgically sterile or postmenopausal to use medically acceptable methods of from the first dose of study drug to 30 days after the last dose of duvelisib and for 12 months after last dose of ofatumumab. Sexually active men, and women using oral contraceptive pills, should also have used barrier contraception
  • Ability to voluntarily sign consent for and adhere to the entire study visit schedule and all protocol requirements
  • Signed and dated institutional review board/independent ethics committee-approved form before any study-specific screening procedures are performed

Exclusion criteria

Exclusion Criteria:

  • Discontinued study participation in Verastem-sponsored IPI-145-07 study
  • Greater than 3 months from confirmed progressive disease on Study IPI-145-07
  • History of Richter's transformation or prolymphocytic leukemia
  • hemolytic anemia or idiopathic thrombocytopenia purpura that was uncontrolled or requires >20 mg daily of prednisone (or equivalent) to maintain >8.0 g/dL or >10,000 μL without transfusion support
  • Known central nervous system (CNS) lymphoma or leukemia; participants with symptoms of CNS disease must have had a negative CT scan or negative diagnostic lumbar puncture prior to first dose
  • Use of any anticancer medication from documented progressive disease on Study IPI-145-07 to enrollment (Note: to manage CLL/SLL-related symptoms were allowed)
  • Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment (defined as requiring IV antimicrobial, antifungal or antiviral agents) (Participants on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met and there is no evidence of active infection at Screening and/or Cycle 1 Day 1 [predose])
  • infection
  • Prior, current, or chronic or infection
  • History of alcohol abuse or chronic liver disease (other than disease to the liver)
  • Unable to receive prophylactic treatment for pneumocystis and herpes simplex virus
  • Baseline corrected with Fridericia's method >480 milliseconds Note: this criterion did not apply to participants with a right or left bundle branch block
  • Concurrent active other than nonmelanoma skin cancer or carcinoma in situ of the cervix, bladder, or prostate not requiring treatment. Participants with previous malignancies were eligible provided that they had been disease-free for ≥2 years
  • History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
  • Unstable or severe uncontrolled medical condition (for example, unstable cardiac function, unstable pulmonary condition), or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, have increased the participant's risk while participating in this study
  • Prior surgery or gastrointestinal dysfunction that may have affected drug absorption (for example, gastric bypass surgery, gastrectomy)
  • Participants to receive duvelisib: Administration of medications or foods that were strong inhibitors or inducers of cytochrome P450 3A within 2 weeks of starting duvelisib
  • Major surgery or invasive intervention within 4 weeks prior to first dose
  • Pregnant or breastfeeding women
  • Participants to receive ofatumumab: to ofatumumab or its .
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    IPI-145

    IPI-145 was administered orally and supplied as 5 mg and 25 mg formulated capsules.

    Drug: IPI-145

  • Active comparator
    Ofatumumab

    Ofatumumab was administered as an intravenous (IV) infusion and was supplied in single-use vials at two strengths, 100 mg/5 milliliters (mL) and 1000 mg/50 mL.

    Drug: Ofatumumab

Interventions

  • PI3K Inhibitor

    Also known as: Duvelisib, Copiktra, PI3K Inhibitor

  • Monoclonal antibody

    Also known as: Arzerra

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of participants with a best response (per investigator assessment) of complete response (CR), CR with incomplete marrow recovery (CRi), partial response (PR), or PR with lymphocytosis (PRwL), according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) or revised International Working Group Response (IWG) Criteria, with modification for treatment-related lymphocytosis. The 95% confidence interval was calculated using exact binomial method. Select IWCLL criteria for tumor load assessed by computed tomography (CT): CR/CRi (CLL only), lymphadenopathy (none \>1.5 centimeters \[cm\]), hepatomegaly/splenomegaly (none); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%). Select IWG criteria for tumor load assessed by CT: CR, lymphadenopathy/hepatomegaly/splenomegaly (normal size); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%).

    Time frame: Until progressive disease (PD), death, or other anticancer therapy is initiated (up to 4.5 years)

Secondary outcomes

  1. Duration of Response (DOR)

    DOR was defined as the time from the first documentation of response per investigator assessment to either PD or death due to any cause. DOR was evaluated using the Kaplan-Meier method based on all treated participants with a documentation of response (that is, CR, CRi, PR, or PRwL) as determined by investigator assessment. Select IWCLL criteria for tumor load assessed by CT: CR/CRi (CLL only), lymphadenopathy (none \>1.5 cm), hepatomegaly/splenomegaly (none); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%). Select IWG criteria for tumor load assessed by CT: CR, lymphadenopathy/hepatomegaly/splenomegaly (normal size); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%).

    Time frame: From the first documentation of response to the first documentation of PD or death due to any cause (up to 4.5 years)

  2. Progression-free Survival (PFS)

    PFS was defined as the time from the first dose of study treatment to the first documentation of either investigator-assessed PD or death resulting from any cause. PFS was determined using the Kaplan-Meier method based on all treated participants with a documentation of response (that is, CR, CRi, PR, or PRwL) as determined by investigator assessment.

    Time frame: From the first dose of study treatment to the first documentation of PD or death from any cause (up to 4.5 years)

07

Results

Posted Feb 21, 2023

Participant flow

All participants previously enrolled in study IPI-145-07 (NCT02004522) who experienced radiologically confirmed disease progression while on treatment in that study were eligible to participate in this study.

Participant flow — Overall Study
MilestoneIPI-145Ofatumumab
Started909
Received at least 1 dose of study drug909
Completed03
Not completed906
Withdrew: Adverse event462
Withdrew: Protocol-specified disease progression232
Withdrew: Death60
Withdrew: Physician decision51
Withdrew: Withdrawal by subject30
Withdrew: Termination of the study by sponsor20
Withdrew: Protocol violation11
Withdrew: Clinical deterioration10
Withdrew: Need treatment for metastatic melanoma10
Withdrew: Treatment interruption >42 days10
Withdrew: Suspected and unconfirmed disease progression10

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was defined as the percentage of participants with a best response (per investigator assessment) of complete response (CR), CR with incomplete marrow recovery (CRi), partial response (PR), or PR with lymphocytosis (PRwL), according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) or revised International Working Group Response (IWG) Criteria, with modification for treatment-related lymphocytosis. The 95% confidence interval was calculated using exact binomial method. Select IWCLL criteria for tumor load assessed by computed tomography (CT): CR/CRi (CLL only), lymphadenopathy (none \>1.5 centimeters \[cm\]), hepatomegaly/splenomegaly (none); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%). Select IWG criteria for tumor load assessed by CT: CR, lymphadenopathy/hepatomegaly/splenomegaly (normal size); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%).

Time frame:
Until progressive disease (PD), death, or other anticancer therapy is initiated (up to 4.5 years)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIPI-145Ofatumumab
Overall Response Rate (ORR)76.7 (66.6 to 84.9)0 (0 to 0)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first documentation of response per investigator assessment to either PD or death due to any cause. DOR was evaluated using the Kaplan-Meier method based on all treated participants with a documentation of response (that is, CR, CRi, PR, or PRwL) as determined by investigator assessment. Select IWCLL criteria for tumor load assessed by CT: CR/CRi (CLL only), lymphadenopathy (none \>1.5 cm), hepatomegaly/splenomegaly (none); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%). Select IWG criteria for tumor load assessed by CT: CR, lymphadenopathy/hepatomegaly/splenomegaly (normal size); PR, lymphadenopathy/hepatomegaly/splenomegaly (decrease ≥50%); PRwL, lymphadenopathy only (decrease ≥50%).

Time frame:
From the first documentation of response to the first documentation of PD or death due to any cause (up to 4.5 years)
Reported as:
Median · months
Duration of Response (DOR)
monthsIPI-145Ofatumumab
Duration of Response (DOR)14.9 (8.55 to 18.6)—
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the first dose of study treatment to the first documentation of either investigator-assessed PD or death resulting from any cause. PFS was determined using the Kaplan-Meier method based on all treated participants with a documentation of response (that is, CR, CRi, PR, or PRwL) as determined by investigator assessment.

Time frame:
From the first dose of study treatment to the first documentation of PD or death from any cause (up to 4.5 years)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsIPI-145Ofatumumab
Progression-free Survival (PFS)15.3 (12.2 to 20.6)—

Adverse events

Collected over 4.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IPI-14520/90 (22.2%)68/90 (75.6%)80/90 (88.9%)
Ofatumumab2/9 (22.2%)4/9 (44.4%)8/9 (88.9%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventIPI-145Ofatumumab
DiarrhoeaGastrointestinal disorders16/901/9
PneumoniaInfections and infestations13/900/9
OedemaGeneral disorders0/901/9
Neutrophil count decreasedInvestigations0/901/9
Humerus fractureInjury, poisoning and procedural complications0/901/9
ColitisGastrointestinal disorders8/900/9
SepsisInfections and infestations4/900/9
Renal failure acuteRenal and urinary disorders4/900/9
Febrile neutropeniaBlood and lymphatic system disorders3/900/9
PyrexiaGeneral disorders3/900/9
Most frequent other events
Showing 10 of 46
Most frequent other events
EventIPI-145Ofatumumab
DiarrhoeaGastrointestinal disorders43/900/9
Infusion related reactionInjury, poisoning and procedural complications0/903/9
NeutropeniaBlood and lymphatic system disorders23/901/9
Vaginal haemorrhageReproductive system and breast disorders0/331/4
Vulvovaginal pruritusReproductive system and breast disorders0/331/4
PyrexiaGeneral disorders21/900/9
RashSkin and subcutaneous tissue disorders21/900/9
AnaemiaBlood and lymphatic system disorders8/902/9
CoughRespiratory, thoracic and mediastinal disorders15/900/9
AstheniaGeneral disorders11/900/9

Baseline characteristics

All-treated analysis set: all participants who received any amount of study drug (IPI-145 or ofatumumab).

Age, Categorical
Age, Categorical(Participants)IPI-145OfatumumabTotal
<=18 years000
Between 18 and 65 years35338
>=65 years55661
Sex: Female, Male
Sex: Female, Male(Participants)IPI-145OfatumumabTotal
Female33437
Male57562
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IPI-145OfatumumabTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White82991
More than one race000
Unknown or Not Reported808
08

Study locations

69 sites
  • La Jolla, California 92093-0698, United States
  • Denver, Colorado 80218, United States
  • Fort Myers, Florida 33916, United States
  • Saint Petersburg, Florida 33705, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02115, United States
  • Saint Louis, Missouri 63130, United States
  • Hackensack, New Jersey 07601, United States
  • New Brunswick, New Jersey 08903, United States
  • New York, New York 10032, United States
  • New York, New York 10065, United States
  • Cincinnati, Ohio 45236, United States
  • Nashville, Tennessee 37203, United States
  • Charlottesville, Virginia 22903, United States
  • Bedford Park, 5042, Australia
  • East Melbourne, 3002, Australia
  • Melbourne, 3058, Australia
  • Linz, 4010, Austria
  • Vienna, 1090, Austria
  • Wels, 4600, Austria
  • Wien, 1130, Austria
  • Bruxelles, 1000, Belgium
  • Bruxelles, 1200, Belgium
  • Gent, 9000, Belgium
  • Leuven, 3000, Belgium
  • Sint-Niklaas, 9100, Belgium
  • Argenteuil Cedex, 95107, France
  • Bobigny, 93009, France
  • Bordeaux, 33076, France
  • Caen, 14033, France
  • Clermont Ferrand, 63100, France
  • La Roche Sur Yon, 85025, France
  • Limoges Cedex, 87042, France
  • Nantes, 44000, France
  • Rennes, 35033, France
  • Vandœuvre-lès-Nancy, 54511, France
  • Berlin, 10707, Germany
  • Leer, 26789, Germany
  • Ulm, 89081, Germany
  • Budapest, 1083, Hungary
  • Budapest, 1122, Hungary
  • Debrecen, 4032, Hungary
  • Gyor, 9024, Hungary
  • Kaposvár, 7400, Hungary
  • Pecs, 7624, Hungary
  • Szeged, 6725, Hungary
  • Catania, 95124, Italy
  • Lecce, 73100, Italy
  • Meldola, 47014, Italy
  • Milano, 20132, Italy
  • Milano, 20162, Italy
  • Padova, 35128, Italy
  • Ravenna, 48121, Italy
  • Rimini, 47923, Italy
  • Roma, 00133, Italy
  • Auckland, 1023, New Zealand
  • Palmerston North, 4442, New Zealand
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Barcelona, 08041, Spain
  • Madrid, 28033, Spain
  • Madrid, 28050, Spain
  • Pamplona, 31008, Spain
  • Bournemouth, BH7 7DW, United Kingdom
  • Leeds, LS9 7TF, United Kingdom
  • Manchester, M20 4BX, United Kingdom
  • Nottingham, NG5 1PB, United Kingdom
  • Oxford, OX3 7JL, United Kingdom
  • Sutton, SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jun 2020 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2023, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2014
First posted
Jan 30, 2014
Start
Dec 2013
Primary completionActual
Jun 12, 2020
CompletionActual
Jun 12, 2020
Results first posted
Feb 21, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02049515
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Jan 30, 2014
Start date
Dec 2013
Primary completion
Jun 12, 2020
Completion
Jun 12, 2020
Results posted
Feb 21, 2023
Last update
Sep 21, 2023

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion